Tobacco mosaic virus nucleic acid interfering interferon suspoemulsion and application thereof

Abstract

The application discloses a tobacco mosaic virus nucleic acid interferon suspoemulsion, which comprises the following components in percentage by mass: tobacco mosaic virus nucleic acid interferon: 2.5-25%; dispersing agent: 1-3%; emulsifying agent: 1-15%; stabilizer: 1-10%; bacteriostatic agent: 0.1-0.8%; pH regulator: 0.1-0.5%; plant oil: 15-40%; nano carrier: 1-3%; and deionized water: the balance. The tobacco mosaic virus nucleic acid interferon is a nucleic acid pesticide TMV-cp(I)-dsRNA against tobacco mosaic virus. The application further discloses application of the suspoemulsion. The specific stabilizer combination effectively inhibits decomposition of the tobacco mosaic virus nucleic acid active ingredient under the storage condition of high temperature 54 DEG C, so that the suspoemulsion has excellent product chemical stability. The specific emulsifying agent combination effectively improves the emulsification performance of the suspoemulsion system, so that the suspoemulsion has excellent product physical stability. The obtained suspoemulsion has a significant prevention and treatment effect on the tobacco mosaic virus.

Description

Technical Field

[0001] This invention belongs to the field of biopesticide technology, specifically, it is a tobacco mosaic virus nucleic acid interferon suspension emulsion and its application. Background Technology

[0002] Plant viral diseases are common in agricultural production and are often referred to as "plant cancer." Tobacco mosaic virus (TMV) is the most representative plant virus. This virus has a wide host range, is highly prevalent in Solanaceae plants, and most easily damages tobacco and tomatoes, causing significant disease. After infecting plants, TMV causes mosaic or necrotic spots on the leaves, resulting in plant deformities, stunting, and even death, leading to substantial yield reductions and lower crop quality.

[0003] The applicant in this case disclosed a nucleic acid pesticide against tobacco mosaic virus (TMV), as well as its synthesis, purification, and application, in CN113717984A. This dsRNA, also known as tobacco mosaic virus nucleic acid interferon, is used to control TMV. Using double-stranded ribonucleic acid as the active ingredient, it employs RNAi technology to interfere with the expression of target genes in pathogens or pests, preventing the translation and synthesis of related proteins. This leads to the target pests or pathogens being unable to perform normal physiological functions, experiencing reduced reproductive capacity, weakened competitiveness, or even death, thereby achieving effective protection of crops and control of pests and diseases.

[0004] The applicant in this case disclosed a tobacco mosaic virus nucleic acid interferon dispersible oil suspension and its application in CN115590038A, which conducted a comprehensive study on dispersible oil suspensions based on vegetable oil as the continuous phase. However, the cost of the vegetable oil used in this formulation is relatively high, which limits its subsequent field application.

[0005] Suspension emulsions are heterogeneous liquid formulations, which can be described as three-phase highly dispersed mixtures or multi-component suspension systems, combining the characteristics of both suspensions and water-based emulsions. Using water as the main solvent, they possess a high flash point and low flammability, improving the safety of production, storage, transportation, and use, while also avoiding the environmental harm caused by the large-scale use of organic solvents. Furthermore, no dust is generated during production and use, making them safer for both producers and users. Summary of the Invention

[0006] Based on the existing technology, the inventors, building upon the dispersible oil suspension of tobacco mosaic virus nucleic acid interferon disclosed in CN115590038A, conducted extensive and in-depth research on the tobacco mosaic virus nucleic acid interferon suspension system. During this research, they unexpectedly discovered for the first time that, through a specific combination of stabilizers, tobacco mosaic virus nucleic acid interferon can achieve good stability in an aqueous suspension system, and that a small amount of stabilizer is sufficient to achieve excellent stabilization.

[0007] Therefore, in a first aspect, the present invention provides a tobacco mosaic virus nucleic acid interferon suspension emulsion, wherein the suspension emulsion comprises the following components by mass percentage:

[0008] Tobacco mosaic virus nucleic acid interferon: 2.5%–25%;

[0009] Dispersant: 1%–3%;

[0010] Emulsifier: 1%–15%;

[0011] Stabilizer: 1%–10%;

[0012] Antibacterial agent: 0.1%–0.8%;

[0013] pH adjuster: 0.1%–0.5%;

[0014] Vegetable oil: 15%–40%;

[0015] Nanocarriers: 1%–3%;

[0016] Deionized water: Balance;

[0017] The tobacco mosaic virus nucleic acid interferon is a nucleic acid pesticide TMV-cp(I)-dsRNA that is effective against tobacco mosaic virus, and is the active ingredient of the suspension emulsion.

[0018] According to the present invention, the dispersant is one or more of fatty alcohol polyoxyethylene ether phosphate, sodium diisooctyl succinate sulfonate, lignin sulfonate, arylphenol polyoxyethylene ether sulfonate, and alkylphenol polyoxyethylene ether phosphate.

[0019] According to the present invention, the emulsifier is a combination of branched dodecylbenzenesulfonate calcium (purity 70%), fatty alcohol polyoxyethylene ether (EO value 9) and EO / PO block polyether (hydroxyl value 92-115 mg KOH / g); preferably, the mass ratio of the three is branched dodecylbenzenesulfonate calcium (purity 70%): fatty alcohol polyoxyethylene ether (EO value 9): EO / PO block polyether (hydroxyl value 92-115 mg KOH / g) = (2.4-4.4): (5.8-7.8): (0.9-2.5).

[0020] According to the present invention, the stabilizer is a combination of 5-aminolevulinic acid, dipotassium hydrogen phosphate, and tris(hydroxymethyl)aminomethane; preferably, the mass ratio of the three is 5-aminolevulinic acid: dipotassium hydrogen phosphate: tris(hydroxymethyl)aminomethane = 5:2:1.

[0021] According to the present invention, the antibacterial agent is one or more of sodium benzoate, potassium sorbate, and Kathon.

[0022] According to the present invention, the vegetable oil is one or more selected from soybean oil, castor oil, olive oil, corn oil, and sunflower seed oil.

[0023] According to the present invention, the pH adjuster is one or more selected from oxalic acid, citric acid, DL-malic acid, lactic acid and triethanolamine.

[0024] According to the present invention, the vegetable oil is one or more of corn oil, soybean oil, and castor oil.

[0025] According to the present invention, the nanocarrier is an amino-modified or coupled silica nanosphere.

[0026] According to a preferred embodiment of the present invention, the mass ratio of the active ingredient, the nucleic acid pesticide TMV-cp(I)-dsRNA which is effective against tobacco mosaic virus, to the amino-modified or coupled silica nanospheres of the nanocarrier is 5:1.

[0027] A second aspect of the present invention provides a method for preparing the above-mentioned tobacco mosaic virus nucleic acid interferon suspension emulsion, comprising the following steps:

[0028] S1. Add tobacco mosaic virus nucleic acid interferon, dispersant, antibacterial agent and stabilizer to vegetable oil in proportion and mix thoroughly to form oil phase;

[0029] S2. Disperse the nanocarrier in deionized water according to the specified ratio to form an aqueous phase;

[0030] S3. Slowly add the oil phase from step S1 to the aqueous phase from step S2. After wet grinding, add emulsifier and pH adjuster and mix thoroughly to obtain tobacco mosaic virus nucleic acid interferon suspension emulsion.

[0031] A third aspect of the present invention provides the application of the above-mentioned tobacco mosaic virus nucleic acid interferon suspension emulsion for the prevention and control of tobacco mosaic virus in agriculture.

[0032] The present invention has the following beneficial effects:

[0033] 1. The suspension emulsion of the present invention effectively inhibits the decomposition of the active components of tobacco mosaic virus nucleic acid under high temperature storage conditions of 54°C through a specific combination of stabilizers, thus giving it excellent product chemical stability.

[0034] 2. By using a specific combination of emulsifiers and leveraging their synergistic effect, the emulsification performance of the tobacco mosaic virus nucleic acid interferon suspension emulsion system is effectively improved, giving it excellent product physical stability.

[0035] 3. The tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention significantly reduces the cost of the formulation, and has the effect of enhancing the growth of tobacco and increasing tobacco yield and income, and has a significant effect on the prevention and control of tobacco mosaic virus. Attached Figure Description

[0036] Figure 1 The results of agarose gel electrophoresis in Example 6 are shown. In the figure: M is the DL5000 DNA Marker; 1 and 2 are samples of Comparative Example 1 after 14 days of storage at room temperature and 54°C, respectively; 3 and 4 are samples of Comparative Example 2 after 14 days of storage at room temperature and 54°C, respectively; 5 and 6 are samples of Example 1 after 14 days of storage at room temperature and 54°C, respectively; 7 and 8 are samples of Example 2 after 14 days of storage at room temperature and 54°C, respectively; 9 and 10 are samples of Example 3 after 14 days of storage at room temperature and 54°C, respectively; 11 and 12 are samples of Example 4 after 14 days of storage at room temperature and 54°C, respectively; 13 and 14 are samples of Example 5 after 14 days of storage at room temperature and 54°C, respectively.

[0037] Figure 2 This is the transmitted light and backscattered light spectrum of the sample prepared in Example 1 in Example 7.

[0038] Figure 3 This is the transmitted light and backscattered light spectrum of the sample prepared in Example 5 in Example 7.

[0039] Figure 4 The transmitted light and backscattered light spectra of the sample prepared in Comparative Example 2 in Example 7 are shown.

[0040] Figure 5 The transmitted light and backscattered light spectra of the sample prepared in Comparative Example 3 in Example 7 are shown.

[0041] Figure 6 The efficacy comparison between the tobacco mosaic virus nucleic acid interferon suspension emulsion of Example 1 and the 5% amino oligosaccharide soluble concentrate is shown. In this case, SG-RNA001 is the tobacco mosaic virus nucleic acid interferon suspension emulsion prepared in Example 1, and the control group is the 5% amino oligosaccharide soluble concentrate (a pesticide registered product). Detailed Implementation

[0042] The inventors of this case unexpectedly discovered for the first time during long-term research that a specific combination of stabilizers can achieve good stability of tobacco mosaic virus interferon in an aqueous suspension system, and that a small amount of stabilizer is needed to achieve excellent stabilization. However, the applicant's disclosure in CN115590038A (A Dispersible Oil Suspension for Tobacco Mosaic Virus Interferon and Its Application) using a stabilizer combination of epoxidized soybean oil, phytic acid, and propyl gallate in an aqueous suspension system accelerates the decomposition of the active ingredient in tobacco mosaic virus interferon.

[0043] The inventors in this case discovered during the experiment that using a combination of 5-aminolevulinic acid, dipotassium hydrogen phosphate, and tris(hydroxymethyl)aminomethane as a stabilizer can effectively inhibit the decomposition of the active ingredient of tobacco mosaic virus nucleic acid interferon and increase the chemical stability of the product.

[0044] To ensure the product quality and long shelf life of tobacco mosaic virus nucleic acid interferon suspension emulsion, the primary challenge is to address the physical stability of the multi-component dispersion system during storage. This technical issue is also a major obstacle to the development and production of this formulation. During storage, especially at higher temperatures, the suspension emulsion exhibits instability phenomena such as oil droplet aggregation, stratification and sedimentation, solid particle and oil-water separation, flocculation and crystal growth, and phase transfer.

[0045] The inventors of this case discovered during the experiment that the synergistic effect of using 70% pure branched dodecylbenzenesulfonate calcium, fatty alcohol polyoxyethylene ether with an EO value of 9, and EO / PO block polyether with a hydroxyl value of 92-115 mg KOH / g can improve the emulsification performance of the tobacco mosaic virus nucleic acid interferon suspension emulsion system and increase the physical stability of the product.

[0046] The treatment of tobacco and tobacco parts using the tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention is carried out directly using conventional treatment methods or by acting on its environment, habitat or storage space, such as soaking, spraying, atomizing, irrigating, smearing, coating, injecting, watering (irrigating) and drip irrigation.

[0047] The present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.

[0048] In the following examples, the ratio of the three components in the stabilizer combination is by weight. The preparation method is to mix the three components, 5-aminolevulinic acid, dipotassium hydrogen phosphate, and tris(hydroxymethyl)aminomethane, evenly according to the mass ratio shown.

[0049] Example 1

[0050] The tobacco mosaic virus nucleic acid interferon suspension emulsion of this embodiment uses tobacco mosaic virus nucleic acid interferon TMV-cp(I)-dsRNA as the active ingredient, combined with dispersants, emulsifiers, stabilizers, antibacterial agents, pH adjusters, vegetable oils, nanocarriers, and deionized water to form a tobacco mosaic virus nucleic acid interferon suspension emulsion. The specific preparation method is as follows:

[0051] According to the formula shown in the table below, firstly, tobacco mosaic virus nucleic acid interferon, dispersant, antibacterial agent, and stabilizer are added to vegetable oil and thoroughly mixed to form an oil phase; then, the nanocarrier is dispersed in deionized water to form an aqueous phase; finally, the oil phase is slowly added to the aqueous phase, and after wet grinding, an emulsifier is added and thoroughly mixed to obtain a 2.5% tobacco mosaic virus nucleic acid interferon suspension. The stabilizer is prepared by uniformly mixing 5-aminolevulinic acid, dipotassium hydrogen phosphate, and tris(hydroxymethyl)aminomethane in a mass ratio of 5:2:1.

[0052]

[0053] Example 2

[0054] The tobacco mosaic virus nucleic acid interferon suspension emulsion of this embodiment uses tobacco mosaic virus nucleic acid interference TMV-cp(I)-dsRNA as the active ingredient, combined with dispersant, emulsifier, stabilizer, antibacterial agent, pH adjuster, vegetable oil, nanocarrier, and deionized water to form a tobacco mosaic virus nucleic acid interferon suspension emulsion. The specific preparation method is the same as in Example 1, and a 5% tobacco mosaic virus nucleic acid interferon suspension emulsion is obtained.

[0055]

[0056]

[0057] Example 3

[0058] The tobacco mosaic virus nucleic acid interferon suspension emulsion of this embodiment uses tobacco mosaic virus nucleic acid interference TMV-cp(I)-dsRNA as the active ingredient, and is formulated with dispersant, emulsifier, stabilizer, antibacterial agent, pH adjuster, vegetable oil, nanocarrier, and deionized water to form a tobacco mosaic virus nucleic acid interferon suspension emulsion. The specific preparation method is the same as in Example 1, and a 10% tobacco mosaic virus nucleic acid interferon suspension emulsion is obtained.

[0059]

[0060] Example 4

[0061] The tobacco mosaic virus nucleic acid interferon suspension emulsion of this embodiment uses tobacco mosaic virus nucleic acid interference TMV-cp(I)-dsRNA as the active ingredient, and is formulated with dispersant, emulsifier, stabilizer, antibacterial agent, pH adjuster, vegetable oil, nanocarrier, and deionized water to form a tobacco mosaic virus nucleic acid interferon suspension emulsion. The specific preparation method is the same as in Example 1, and a 20% tobacco mosaic virus nucleic acid interferon suspension emulsion is obtained.

[0062]

[0063] Example 5

[0064] The tobacco mosaic virus nucleic acid interferon suspension emulsion of this embodiment uses tobacco mosaic virus nucleic acid interference TMV-cp(I)-dsRNA as the active ingredient, combined with dispersant, emulsifier, stabilizer, antibacterial agent, pH adjuster, vegetable oil, nanocarrier, and deionized water to form a tobacco mosaic virus nucleic acid interferon suspension emulsion. The specific preparation method is the same as in Example 1, and a 25% tobacco mosaic virus nucleic acid interferon suspension emulsion is obtained.

[0065]

[0066] Comparative Example 1

[0067] The formulation and preparation method of the tobacco mosaic virus nucleic acid interferon suspension emulsion in this comparative example are the same as those in Example 1. The difference is the ratio of the stabilizer, specifically: the ratio of 5-aminolevulinic acid, dipotassium hydrogen phosphate and tris(hydroxymethyl)aminomethane is 1:2:5.

[0068]

[0069] Comparative Example 2

[0070] The formulation and preparation method of the tobacco mosaic virus nucleic acid interferon suspension emulsion in this comparative example are the same as those in Example 1. The difference is the emulsifier, which is a combination of calcium dodecylbenzenesulfonate (purity 70%), fatty alcohol polyoxyethylene ether (EO value 3) and EO / PO block polyether (hydroxyl value 40-60 mg KOH / g).

[0071]

[0072]

[0073] Comparative Example 3

[0074] The formulation and preparation method of the tobacco mosaic virus nucleic acid interferon suspension emulsion in this comparative example are the same as those in Example 1. The difference is the ratio of the active ingredient to the nanocarrier, that is, the ratio of the nucleic acid pesticide TMV-cp(I)-dsRNA to amino-modified / coupled silica nanospheres is 1:3.

[0075]

[0076] Example 6: Stability Test (Chemical Stability)

[0077] The N-glycosidic bonds and phosphodiester bonds between the bases and pentose sugars in the tobacco mosaic virus interferon molecule used in this invention are easily hydrolyzed under the influence of physical, chemical, and biological factors, causing RNA chain breakage and subsequent degradation of the interferon molecule. Due to its easily decomposed nature, this embodiment investigates the chemical stability of the suspension emulsion prepared with tobacco mosaic virus interferon as the active ingredient.

[0078] The tobacco mosaic virus nucleic acid interferon suspensions prepared in Comparative Examples 1-2 and Examples 1-5 were subjected to thermal storage stability tests, which were conducted in accordance with the "Liquid Preparations" section of GB / T 19136-2021.

[0079] The effective component (dsRNA fragment length 482bp) was detected by agarose gel electrophoresis. The agarose concentration used in this example was 1.5%. Samples from Comparative Examples 1 and 2, and Examples 1, 2, 3, 4, and 5, stored at room temperature and after 14 days of heat storage at 54℃, were diluted to the same concentration. 10 μL of each sample was loaded, and electrophoresis was performed at 150V for 20 min. Images were then captured using a gel imaging system. The results are shown below. Figure 1 As shown.

[0080] Figure 1 The results showed that the nucleic acid bands in Examples 1-5 were mainly located at 500 bp on the DL5000 Marker, and no degradation was observed in the samples after storage at room temperature and after 14 days of heat storage at 54°C. In contrast, Comparative Examples 1 and 2 showed nucleic acid bands not only at 500 bp on the DL5000 Marker but also in the 100-250 bp range, indicating that different stabilizer ratios and emulsifier combinations affect the chemical stability of tobacco mosaic virus nucleic acid interferon.

[0081] Example 7: Stability Test (Physical Stability)

[0082] The tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention is a three-phase highly dispersed multi-component suspension system. During storage, especially under high temperature conditions, unstable phenomena such as oil droplet aggregation, stratification and sedimentation, solid particle and oil-water separation, flocculation and crystal growth, and transfer between different phases may occur.

[0083] Therefore, in order to verify the physical stability of the tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention, the physical stability of the samples prepared in Example 1, Example 5 and Comparative Examples 2 and 3 was tested using an AGS multiple light scattering instrument.

[0084] An AGS (Automatic Multiple Light Scattering) instrument uses near-infrared light as its light source and has a transmitted light detector and a backscattered light detector. The light source, along with the transmitted and backscattered light detectors, forms the measurement probe. The measurement probe measures every 40 μm from the bottom to the top of the sample cell; completing this measurement from bottom to top is called one scan. Over time, due to the instability of the sample, both transmitted and backscattered light will change, indicating a change in the particle size and / or concentration of the sample particles.

[0085] Detection parameters: Sample volume 20 mL, detection stability 54℃; scan once every hour, for 24 hours; detection results as follows. Figures 2-5 As shown.

[0086] Figure 4 and Figure 5 The backscattered light scans show that the backscattered light intensity decreases over time, becoming negative, indicating that the particles in the samples prepared in Comparative Examples 2 and 3 are increasing in size, gradually exceeding 600 nm, and exhibiting particle aggregation. From... Figure 2 , Figure 3 It can be seen that the samples prepared in Examples 1 and 5 exhibit excellent microstructural stability, with particles being uniformly distributed, thus giving the tobacco mosaic virus nucleic acid interferon suspension system excellent physical stability. This demonstrates that different combinations of emulsifiers and different ratios of active ingredients to nanocarriers all affect the physical stability of tobacco mosaic virus nucleic acid interferon.

[0087] Application Example 1

[0088] This application example was conducted in Jijie Town, Xundian County, Kunming City, Yunnan Province, a major tobacco-producing area where tobacco leaf virus disease occurs year-round.

[0089] The experiment included 10 treatments: Examples 1 to 5, tobacco mosaic virus nucleic acid interferon suspension emulsions prepared by Comparative Examples 1 to 3, control agent was 5% amino oligosaccharide soluble concentrate (a pesticide registered product), and water control, with each treatment repeated 3 times.

[0090] A total of three applications of pesticide were made throughout the entire growth period: spraying the plants according to the experimental treatment design two days before or on the day of transplanting, 14 days after transplanting, and 28 days after transplanting. The water usage was 45 kg per acre. Ten days after the third application, at the budding stage, the incidence of tobacco mosaic virus was investigated. Five representative sampling points were randomly selected from each plot, with 10 tobacco plants surveyed at each point, for a total of 50 plants surveyed. If fewer than 50 plants were available, all plants were surveyed. The survey was conducted at different levels, with the total number of plants surveyed, the number of diseased plants at each level, and the disease incidence rate, disease index, and control effect calculated.

[0091] Grading standards:

[0092] Grade 0: The entire plant is disease-free.

[0093] Grade 1: The veins of the heart leaves are clear or there is slight mosaic pattern. The diseased plants are not obviously stunted.

[0094] Grade 3: 1 / 3 of the leaves are variegated but not deformed, or the plant is dwarfed to more than 3 / 4 of its normal height.

[0095] Grade 5: 1 / 3 to 1 / 2 of the leaves are mosaic, or a few leaves are deformed, or the main vein turns black, or the plant is stunted to 2 / 3 to 3 / 4 of its normal height.

[0096] Level 7: 1 / 2 to 2 / 3 of the leaves are mosaic, deformed, or have necrosis of the main and lateral veins, or the diseased plant is stunted to 1 / 2 to 2 / 3 of its normal height.

[0097] Level 9: The entire plant has mosaic patterns on its leaves, is severely deformed or necrotic, or the diseased plant is stunted to more than half the normal height.

[0098] Methods for calculating drug efficacy:

[0099]

[0100]

[0101]

[0102] The results of field trials for the control of tobacco mosaic virus disease are shown in Table 1 below:

[0103] Table 1: Results of field efficacy trials against tobacco mosaic virus.

[0104]

[0105]

[0106] *: Disease index (%) of the water control group.

[0107] As shown in Table 1, the final control efficacy of the tobacco mosaic virus nucleic acid interferon suspension emulsions in Examples 1 to 5 against tobacco mosaic virus disease was all above 70%, with the highest reaching above 80%, which was significantly better than that of Comparative Example 1, Comparative Example 2, Comparative Example 3 and the control agent. Moreover, no phytotoxicity was produced, and the control effect was significant.

[0108] Figure 6 The photograph shows a comparison of the efficacy of the tobacco mosaic virus nucleic acid interferon suspension emulsion of Example 1 and the 5% amino oligosaccharide soluble concentrate. It can be seen that the tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention can enhance the growth of tobacco against tobacco mosaic virus.

[0109] Therefore, the tobacco mosaic virus nucleic acid interferon suspension emulsion of the present invention has a significantly better control effect on tobacco mosaic virus than the control agent, and also enhances the growth of tobacco and increases tobacco yield and income, making it worthy of widespread application in tobacco production.

Claims

1. A tobacco mosaic virus nucleic acid interfering interferon suspoemulsion characterized in that, comprise the following components by mass percentage: Tobacco mosaic virus nucleic acid interferon: 2.5% to 25%; dispersant: 1% to 3%; emulsifier: 1% to 15%; stabilizer: 1% to 10%; bacteriostatic agent: 0.1% to 0.8%; pH regulator: 0.1% to 0.5%; plant oil: 15% to 40%; nano carrier: 1% to 3%; deionized water: the balance; The tobacco mosaic virus nucleic acid interferon is an anti-tobacco mosaic virus nucleic acid pesticide TMV-cp(I)-dsRNA, which is the active ingredient of the suspoemulsion; The dispersant is one or more of fatty alcohol polyoxyethylene ether phosphate, sodium diisooctyl sulfosuccinate, lignin sulfonate, aryl phenol polyoxyethylene ether sulfonate, and alkyl phenol polyoxyethylene ether phosphate; The emulsifier is a combination of calcium branched dodecyl benzene sulfonate with a purity of 70%, fatty alcohol polyoxyethylene ether with an EO value of 9, and EO / PO block polyether with a hydroxyl value of 92 to 115 mg KOH / g; The stabilizer is a combination of 5-amino levulinic acid, dipotassium hydrogen phosphate, and tris(hydroxymethyl) aminomethane; The bacteriostatic agent is one or more of sodium benzoate, potassium sorbate, and kasun; The pH regulator is one or more of oxalic acid, citric acid, DL-malic acid, lactic acid, and triethanolamine; The plant oil is one or more of soybean oil, castor oil, olive oil, corn oil, and sunflower seed oil; The nano carrier is amino-modified or coupled silica nanospheres.

2. The tobacco mosaic virus nucleic acid interfering interferon suspoemulsion according to claim 1, characterized in that, The mass ratio of the three components in the combination of the emulsifier is calcium branched dodecyl benzene sulfonate with a purity of 70%: fatty alcohol polyoxyethylene ether with an EO value of 9: EO / PO block polyether with a hydroxyl value of 92 to 115 mg KOH / g = (2.4 to 4.4):(5.8 to 7.8):(0.9 to 2.5).

3. The tobacco mosaic virus nucleic acid interfering emulsion in water suspension according to claim 1, characterized in that, The mass ratio of the three components in the combination of the stabilizer is 5-amino levulinic acid: dipotassium hydrogen phosphate: tris(hydroxymethyl) aminomethane = 5:2:

1.

4. The tobacco mosaic virus nucleic acid interfering emulsion in water suspension according to claim 1, characterized in that, The plant oil is one or more of corn oil, soybean oil, and castor oil.

5. The tobacco mosaic virus nucleic acid interfering emulsion in water suspension according to claim 1, characterized in that, The mass ratio of the active ingredient, anti-tobacco mosaic virus nucleic acid pesticide TMV-cp(I)-dsRNA, to the nano carrier, amino-modified or coupled silica nanospheres, is 5:

1.

6. Use of a Tobacco Mosaic Virus Nucleic Acid Interfering Suspension Concentrate Emulsion according to any one of claims 1 to 5, characterized in that, For controlling tobacco mosaic virus in agriculture.

Images